Role of Nmi in retarding breast tumor growth.

Nmi 在延缓乳腺肿瘤生长中的作用。

基本信息

  • 批准号:
    8433522
  • 负责人:
  • 金额:
    $ 24.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-03-04 至 2014-12-31
  • 项目状态:
    已结题

项目摘要

Research in our laboratory focuses on understanding the role of N-Myc interactor (Nmi) in cancer biology [1]. Our interest in this molecule was triggered when we saw that its expression was diminished in aggressive breast cancer cell lines. Interestingly though, Nmi expression could be induced in these cells using interferon-¿ (IFN-¿) [1]. We found that the induced mRNA had a wild type sequence, implying that the induced Nmi protein was capable of its normal biological activities. To test its functional role, we constitutively expressed Nmi in the human breast cancer cell line, MDA-MB- 231. Functional studies of the expressors showed that Nmi reduced the ability of tumor cells to invade and grow under anchorage independent conditions. Xenograft studies in nude mice showed that Nmi expressors had reduced tumor growth in vivo [1]. Further analysis of these expressors revealed that Dickkopf-1 (Dkk1), a soluble inhibitor of the Wnt/¿- catenin signaling pathway, was significantly upregulated in the Nmi expressing clones concurrent with reduced levels of the critical transcription co-factor of Wnt pathway, ¿-catenin. Dkk1 has been reported to suppress primary tumor growth rates in several studies involving breast cancer [2, 3] and is a factor implicated in the anti-tumor effects elicited by IFN-¿ [4]. Wnt/¿-catenin signaling is important in development as well as cell proliferation. While previously shown to be a critical player in colon cancer progression, the role of Wnt/¿-catenin signaling in breast cancer is not clearly defined [5]. The overall objective of this proposed work is to understand the regulation of Wnt/¿-catenin signaling by Nmi and to determine the role of this pathway in suppression of breast tumor growth. HYPOTHESIS Inhibition of the Wnt/¿-catenin signaling pathway by upregulation of Dkk1 is critical to the role of Nmi in reducing tumor growth. Aim 1: To test the hypothesis that knockdown of Nmi expression will activate the Wnt/¿-catenin signaling. Aim 2: To determine the mechanism of regulation of Dkk1 and ¿-catenin by Nmi. Aim 3: To evaluate the role of Dkk1 in mediating the retardation of tumor growth by Nmi. Aim 4: To determine correlation between loss of Nmi expression and activated Wnt/¿-catenin signaling in patient derived breast cancer specimens.
我们实验室的研究重点是了解N-Myc相互作用因子(Nmi)在癌症中的作用 生物学[1]。当我们看到它的表达是 在侵袭性乳腺癌细胞系中减少。有趣的是,Nmi的表达可能是 在这些细胞中使用干扰素-<$(IFN-<$)诱导[1]。我们发现,诱导的mRNA具有野生型 序列分析表明,诱导表达的Nmi蛋白具有正常的生物学活性。测试 其功能作用,我们组成型表达Nmi在人乳腺癌细胞系,MDA-MB- 231.表达子的功能研究表明,Nmi降低了肿瘤细胞侵袭的能力 并在不依赖锚定的条件下生长。裸鼠异种移植研究表明,Nmi 在体内,表达者的肿瘤生长减少[1]。 对这些表达子的进一步分析表明,Dickkopf-1(Dkk1),一种可溶性Wnt/Wnt抑制剂, 连环蛋白信号通路,在Nmi表达克隆中显著上调, 降低Wnt途径的关键转录辅因子--连环蛋白的水平。DKK 1已经 据报道,在涉及乳腺癌的几项研究中抑制原发性肿瘤生长率[2,3], 一种与IFN-γ引起的抗肿瘤作用有关的因子[4]。Wnt/β-catenin信号传导很重要 在发育和细胞增殖中的作用。虽然以前被证明是结肠癌的关键球员, 尽管Wnt/β-catenin信号在乳腺癌进展中的作用尚未明确[5]。 这项工作的总体目标是了解Wnt/连环蛋白信号转导的调控 通过Nmi,并确定该途径在抑制乳腺肿瘤生长中的作用。 假设 通过上调Dkk1来抑制Wnt/<$-连环蛋白信号传导通路对于以下作用至关重要: 减少肿瘤生长。 目的1:验证Nmi表达的敲低将激活Wnt/â-连环蛋白的假设 信号 目的2:探讨Nmi对Dkk 1和<$-catenin的调控机制。 目的3:探讨Dkk 1在Nmi抑制肿瘤生长中的作用。 目的4:确定Nmi表达缺失与活化Wnt/<$-连环蛋白之间的相关性 患者来源的乳腺癌样本中的信号传导。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rajeev S Samant其他文献

Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-κB activation
  • DOI:
    10.1186/1476-4598-6-6
  • 发表时间:
    2007-01-16
  • 期刊:
  • 影响因子:
    33.900
  • 作者:
    Rajeev S Samant;David W Clark;Rebecca A Fillmore;Muzaffer Cicek;Brandon J Metge;Kondethimmana H Chandramouli;Ann F Chambers;Graham Casey;Danny R Welch;Lalita A Shevde
  • 通讯作者:
    Lalita A Shevde

Rajeev S Samant的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rajeev S Samant', 18)}}的其他基金

A novel strategy to debilitate breast cancer metastasis
削弱乳腺癌转移的新策略
  • 批准号:
    10508990
  • 财政年份:
    2022
  • 资助金额:
    $ 24.97万
  • 项目类别:
Mechanisms that impact metastatic progression of triple negative breast cancer
影响三阴性乳腺癌转移进展的机制
  • 批准号:
    10009841
  • 财政年份:
    2017
  • 资助金额:
    $ 24.97万
  • 项目类别:
Mechanisms that impact metastatic progression of triple negative breast cancer
影响三阴性乳腺癌转移进展的机制
  • 批准号:
    10347166
  • 财政年份:
    2017
  • 资助金额:
    $ 24.97万
  • 项目类别:
Mechanisms that impact metastatic progression of triple negative breast cancer
影响三阴性乳腺癌转移进展的机制
  • 批准号:
    10554270
  • 财政年份:
    2017
  • 资助金额:
    $ 24.97万
  • 项目类别:
Dietary intervention of non-classical Wnt signaling
非经典 Wnt 信号传导的饮食干预
  • 批准号:
    9889045
  • 财政年份:
    2016
  • 资助金额:
    $ 24.97万
  • 项目类别:
Dietary intervention of non-classical Wnt signaling
非经典 Wnt 信号传导的饮食干预
  • 批准号:
    9240612
  • 财政年份:
    2016
  • 资助金额:
    $ 24.97万
  • 项目类别:
Role of Nmi in retarding breast tumor growth.
Nmi 在延缓乳腺肿瘤生长中的作用。
  • 批准号:
    7885957
  • 财政年份:
    2010
  • 资助金额:
    $ 24.97万
  • 项目类别:
Role of Nmi in retarding breast tumor growth.
Nmi 在延缓乳腺肿瘤生长中的作用。
  • 批准号:
    8038299
  • 财政年份:
    2010
  • 资助金额:
    $ 24.97万
  • 项目类别:
Role of Nmi in retarding breast tumor growth.
Nmi 在延缓乳腺肿瘤生长中的作用。
  • 批准号:
    8206858
  • 财政年份:
    2010
  • 资助金额:
    $ 24.97万
  • 项目类别:

相似海外基金

Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
加强监管系统和标准化活动方面的合作,以增加全球获得安全有效的生物产品的机会。
  • 批准号:
    10448926
  • 财政年份:
    2021
  • 资助金额:
    $ 24.97万
  • 项目类别:
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
加强监管系统和标准化活动方面的合作,以增加全球获得安全有效的生物产品的机会。
  • 批准号:
    10491861
  • 财政年份:
    2021
  • 资助金额:
    $ 24.97万
  • 项目类别:
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
加强监管系统和标准化活动方面的合作,以增加全球获得安全有效的生物产品的机会。
  • 批准号:
    10675535
  • 财政年份:
    2021
  • 资助金额:
    $ 24.97万
  • 项目类别:
EPSRC Centre for Doctoral Training in Bioprocess Engineering Leadership (Complex Biological Products Manufacture)
EPSRC 生物过程工程领导力博士培训中心(复杂生物制品制造)
  • 批准号:
    EP/S021868/1
  • 财政年份:
    2019
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Training Grant
Exploring interactions and benefits of novel microbial biological products in blueberry propagation
探索新型微生物生物制品在蓝莓繁殖中的相互作用和益处
  • 批准号:
    529840-2018
  • 财政年份:
    2018
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Applied Research and Development Grants - Level 1
GOALI: Collaborative Research: Industrial Implementation of Smart Biopolymers for Purification of Biological Products
目标:合作研究:用于生物制品纯化的智能生物聚合物的工业实施
  • 批准号:
    1403724
  • 财政年份:
    2014
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Standard Grant
GOALI: Collaborative Research: Industrial Implementation of Smart Biopolymers for Purification of Biological Products
目标:合作研究:用于生物制品纯化的智能生物聚合物的工业实施
  • 批准号:
    1403697
  • 财政年份:
    2014
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Standard Grant
Formulation and delivery approaches for water soluble biological products delivered through the skin focussing on L-Ascorbic Acid.
通过皮肤输送的水溶性生物产品的配方和输送方法,重点是 L-抗坏血酸。
  • 批准号:
    131690
  • 财政年份:
    2014
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Feasibility Studies
Formulation and stability of biological products for skin delivery focussing on Retinol.
以视黄醇为重点的皮肤输送生物制品的配方和稳定性。
  • 批准号:
    131338
  • 财政年份:
    2013
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Feasibility Studies
Demonstrate the effectiveness of antimicrobial protection of new types of Biological Products
展示新型生物制品抗菌保护的有效性
  • 批准号:
    429734-2011
  • 财政年份:
    2012
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Experience Awards (previously Industrial Undergraduate Student Research Awards)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了